Quick Answer
RenovoRx, Inc. reported Operating Income Loss of -$12.51 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -14.0% in Operating Income Loss from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$910.0 thousand | Q1 2021: -$1.05 million | Q2 2021: -$866.0 thousand | Q3 2021: -$1.40 million | Q1 2022: -$3.01 million | Q2 2022: -$2.61 million | Q3 2022: -$2.16 million | Q1 2023: -$3.26 million | Q2 2023: -$3.38 million | Q3 2023: -$2.98 million | Q1 2024: -$2.48 million | Q2 2024: -$3.03 million | Q3 2024: -$2.83 million | Q1 2025: -$3.11 million | Q2 2025: -$2.68 million | Q3 2025: -$3.20 million.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Operating Income Loss has declined by 290.4%.
- Historical annual values: Fiscal year 2025: -$12.51 million | Fiscal year 2024: -$10.97 million | Fiscal year 2023: -$11.40 million | Fiscal year 2022: -$9.95 million | Fiscal year 2021: -$5.67 million | Fiscal year 2020: -$3.20 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: